Skip to main content

carbidopa; levodopa

Generic: CARBIDOPA; LEVODOPA·Brand: CARBIDOPA AND LEVODOPA, CARBILEV, CREXONT, DHIVY, DUOPA, PARCOPA, RYTARY, SINEMET, SINEMET CR

carbidopa; levodopa: developed by 2 companies · 1 FDA decision.

carbidopa; levodopa evidence translation

What we can confirm

1 FDA record

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

What is verified about carbidopa; levodopa, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

treatment of Parkinson's disease

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
AbbVie Inc. (ABBV)Approved
Amneal Pharmaceuticals, Inc. (AMRX)
treatment of Parkinson's disease
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE DUOPA ® is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. DUOPA is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease ( 1 )(ABBV)FDA ↗
NDA203952Type 3 - New Dosage FormOrphan DrugStandardOtherSuspension

Frequently asked questions

Who is developing carbidopa; levodopa?

carbidopa; levodopa is being developed by AbbVie Inc., Amneal Pharmaceuticals, Inc..

What is carbidopa; levodopa's latest FDA decision?

The most recent tracked FDA decision for carbidopa; levodopa is Approval for 1 INDICATIONS AND USAGE DUOPA ® is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. DUOPA is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease ( 1 ), dated January 9, 2015.